Anti-Caspase-9 antibody [EPR18868]
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
5
(1 Review)
|
(61 Publications)
- IP
Supplier Data
Immunoprecipitation - Anti-Caspase-9 antibody [EPR18868] (AB184786)
Caspase 9 was immunoprecipitated from 1mg of NIH/3T3 whole cell lysate (Mouse embyro fibroblast cells) treated with 1μM staurosporine for 4h with ab184786 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab184786 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1 : NIH/3T3 whole cell lysate treated with 1μM staurosporine for 4h,10ug (Input).
Lane 2 : ab184786 IP in NIH/3T3 whole cell lysate treated with 1μM staurosporine for 4h.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab184786 in NIH/3T3 whole cell lysate treated with 1μM staurosporine for 4h.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 10 seconds.
The product has better affinity to procaspase-9. The cleaved form p37 could not be observed even with 3 minutes exposure time.
All lanes:
Immunoprecipitation - Anti-Caspase-9 antibody [EPR18868] (ab184786)
Predicted band size: 46 kDa
false
- IP
Supplier Data
Immunoprecipitation - Anti-Caspase-9 antibody [EPR18868] (AB184786)
Caspase 9 was immunoprecipitated from 1mg of C6 whole cell lysate (Rat glial tumor cells) treated with 1μM staurosporine for 4h with ab184786 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab184786 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1 : C6 whole cell lysate treated with 1μM staurosporine for 4h, 10ug (Input).
Lane 2 : ab184786 IP in C6 whole cell lysate treated with 1μM staurosporine for 4h.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab184786 in C6 whole cell lysate treated with 1μM staurosporine for 4h.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 3 seconds.
The product has better affinity to procaspase-9. The cleaved form p37 could be observed with longer exposure time.
All lanes:
Immunoprecipitation - Anti-Caspase-9 antibody [EPR18868] (ab184786)
Predicted band size: 46 kDa
false
- WB
Supplier Data
Western blot - Anti-Caspase-9 antibody [EPR18868] (AB184786)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-Caspase-9 antibody [EPR18868] (ab184786) at 1/1000 dilution
Lane 1:
Untreated NIH/3T3 (Mouse embyro fibroblast cell line) whole cell lysate at 20 µg
Lane 2:
NIH/3T3 whole cell lysate treated with 1 µM staurosporine for 4 hours at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 46 kDa
Observed band size: 37 kDa,39 kDa,50 kDa
false
Exposure time: 15s
- WB
Supplier Data
Western blot - Anti-Caspase-9 antibody [EPR18868] (AB184786)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-Caspase-9 antibody [EPR18868] (ab184786) at 1/1000 dilution
Lane 1:
Mouse brain lysate at 10 µg
Lane 2:
Mouse heart lysate at 10 µg
Lane 3:
Mouse spleen lysate at 10 µg
Lane 4:
Rat brain lysate at 10 µg
Lane 5:
Rat heart lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 46 kDa
Observed band size: 37 kDa,39 kDa,50 kDa
false
Exposure time: 20s
- WB
Supplier Data
Western blot - Anti-Caspase-9 antibody [EPR18868] (AB184786)
Blocking/Dilution buffer : 5% NFDM/TBST.
The p39 and p37 subunits were inhibited when the caspase activity was blocked by the caspase inhibitor, Z-VAD-FMK.
All lanes:
Western blot - Anti-Caspase-9 antibody [EPR18868] (ab184786) at 1/1000 dilution
Lane 1:
Untreated C6 (Rat glial tumor cells) whole cell lysate at 20 µg
Lane 2:
C6 whole cell lysate treated with 50 µm Z-VAD-FMK for 0.5 hour at 20 µg
Lane 3:
C6 whole cell lysate treated with 50 µm Z-VAD-FMK for 1 hour at 20 µg
Lane 4:
C6 whole cell lysate treated with 1 µm staurosporine for 4 hours at 20 µg
Lane 5:
C6 whole cell lysate treated with 50 µm Z-VAD-FMK for 1 hour, then treated with 1 µM staurosporine for 4 hours at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 46 kDa
Observed band size: 37 kDa,39 kDa,50 kDa
false
Exposure time: 10s
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (61)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in pharmacology 16:1600435 PubMed40918528
2025
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 15:28482 PubMed40759713
2025
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 32: PubMed40280112
2025
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 15:11698 PubMed40188200
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 15:1445597 PubMed39449968
2024
Applications
Unspecified application
Species
Unspecified reactive species
Pharmaceuticals (Basel, Switzerland) 17: PubMed39338354
2024
Applications
Unspecified application
Species
Unspecified reactive species
Heliyon 10:e36176 PubMed39224278
2024
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 14:10959 PubMed38745034
2024
Applications
Unspecified application
Species
Unspecified reactive species
International neurourology journal 28:22-32 PubMed38569617
2024
Applications
Unspecified application
Species
Unspecified reactive species
Aging 15:15196-15212 PubMed38149979
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com